Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling.
The response of cancer patients to interferon (IFN) treatment is long-lasting, indicating that IFN may act on small cancer stem cell populations. Glioma-initiating cells (GICs) can self-renew and induce the formation of heterogeneously differentiated tumor cells and are resistant to chemotherapeutic agents like temozolomide. In this study, we showed that via STAT3 signaling, IFN-beta suppressed the proliferation, self-renewal, and tumorigenesis of GICs, induced their terminal differentiation to mature oligodendroglia-like cells, and exhibited synergistic cytotoxicity with temozolomide. Therefore, IFN may be a potential therapeutic agent for inducing the terminal differentiation of GICs.
Yuki
Kanako
K
Center for Genetic and Regenerative Medicine, Nagoya University Hospital, Nagoya, Japan.
Natsume
Atsushi
A
Yokoyama
Hidenori
H
Kondo
Yutaka
Y
Ohno
Masasuke
M
Kato
Takenori
T
Chansakul
Phassarin
P
Ito
Motokazu
M
Kim
Seung-Up
SU
Wakabayashi
Toshihiko
T
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D005909:Glioblastoma / Q000378:metabolism*; D006801:Humans; D016899:Interferon-beta / Q000494:pharmacology*; D009836:Oligodendroglia / Q000187:drug effects* / Q000473:pathology; D050796:STAT3 Transcription Factor / Q000502:physiology*; D015398:Signal Transduction; D000077204:Temozolomide
D000970:Antineoplastic Agents; D050796:STAT3 Transcription Factor; D016899:Interferon-beta; D003606:Dacarbazine; D000077204:Temozolomide